KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biocryst Pharmaceuticals (BCRX) Return on Sales (2023 - 2025)

Biocryst Pharmaceuticals' Return on Sales history spans 9 years, with the latest figure at 347.24% for Q4 2025.

  • For Q4 2025, Return on Sales rose 34744.0% year-over-year to 347.24%; the TTM value through Dec 2025 reached 0.56%, up 76.0%, while the annual FY2025 figure was 0.3%, 50.0% up from the prior year.
  • Return on Sales reached 347.24% in Q4 2025 per BCRX's latest filing, up from 0.08% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 347.24% in Q4 2025 to a low of 1.3% in Q3 2023.
  • Average Return on Sales over 3 years is 28.64%, with a median of 0.16% recorded in 2024.
  • The largest YoY upside for Return on Sales was 34744bps in 2025 against a maximum downside of 15bps in 2025.
  • A 3-year view of Return on Sales shows it stood at 0.52% in 2023, then surged by 61bps to 0.2% in 2024, then surged by 170556bps to 347.24% in 2025.
  • Per Business Quant, the three most recent readings for BCRX's Return on Sales are 347.24% (Q4 2025), 0.08% (Q3 2025), and 0.03% (Q2 2025).